Improvement of metabolic disorders and visceral fat obesity by the β3-adrenoceptor agonist (R∗,R∗)-(±)-methyl -4-[2-[2-hydroxy -2-(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents
- 22 November 1996
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 52 (10) , 1529-1535
- https://doi.org/10.1016/s0006-2952(96)00552-7
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- β1‐ and β2‐adrenoceptor antagonist activities of ICI‐215001, a putative β3‐adrenoceptor agonistBritish Journal of Pharmacology, 1994
- Tissue distribution of beta 3-adrenergic receptor mRNA in man.Journal of Clinical Investigation, 1993
- Metabolism of adipose tissue in intraabdominal depots in severely obese men and womenMetabolism, 1990
- Direct evidence for the atypical nature of functional β‐adrenoceptors in rat adipocytesBritish Journal of Pharmacology, 1989
- Molecular Characterization of the Human β 3 -Adrenergic ReceptorScience, 1989
- Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesityMetabolism, 1987
- Improved Glycemic Control in C57BI/KsJ (db/db) Mice After Treatment with the Thermogenic β-Adrenoceptor Agonist, BRL 26830Diabetes, 1985
- Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugsNature, 1984
- Diabetic Hypertriglyceridemia: Evidence for Three Clinical SyndromesDiabetes, 1981
- Differentiation of Receptor Systems activated by Sympathomimetic AminesNature, 1967